FIELD: medicine.
SUBSTANCE: invention refers to drugs and concerns a pharmaceutical combination containing the effective amount of an anticancer compound, representing VEGF Trap 
, in combination with the effective quantity of combretastatin derivative chosen of: combretastatin A-4, a product of formula 
and combretastatin derivative of formula 
for treating solid tumours.
EFFECT: combinations according to the invention provide essential reduction of tumour volume development in comparison with separate introduction of each compound.
3 cl, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-CANCER COMBINATIONS CONTAINING VEGF INHIBITOR AND IRINOTECAN | 2008 |
|
RU2471483C2 |
| ANTICANCER COMPOSITIONS CONTAINING AGENT INHIBITING VEGF AND 5FU OR ONE OF ITS DERIVATIVES | 2005 |
|
RU2384344C2 |
| APPLICATION OF MEDICATIONS, BINDING EDG-RECEPTOR, IN TREATMENT OF CANCER DISEASE | 2008 |
|
RU2426555C2 |
| COMBINATIONS INCLUDING EPOTHILONES, AND THEIR PHARMACEUTICAL APPLICATION | 2002 |
|
RU2375058C2 |
| USE OF NOX INHIBITORS FOR TREATMENT OF CANCER | 2018 |
|
RU2780354C2 |
| APPLICATION OF EDG-RECEPTOR BINDING AGENT IN CANCER THERAPY | 2003 |
|
RU2358717C2 |
| USE OF 4-PYRIDYLMETHYLPHTHALAZINES IN CANCER TREATMENT | 2002 |
|
RU2320344C2 |
| FLUOROALKOXY-COMBRETASTATIN DERIVATIVES, USE AND SYNTHESIS METHODS THEREOF | 2006 |
|
RU2417216C2 |
| TREATMENT OF CANCER BY PARVOVIRUS IN COMBINATION WITH BEVACIZUMAB | 2016 |
|
RU2679442C1 |
| THERAPY WITH DIVIDED DOSAGES OF AGENTS OF VASCULODESTROYING ACTIVITY | 2001 |
|
RU2279277C2 |
